3 Results for "

KRASG12D-mutant cancers

" in MedChemExpress (MCE) Product Catalog:
Products (3)

3 Results for "KRASG12D-mutant cancers" in MCE Product Catalog:

Cat. No.: HY-176870
CAS No.: 3033641-67-4
Target:  

Ras

Research Areas:  

Cancer

KRAS-IN-42 (Compound Z1063) is a covalent KRAS G12D mutants inhibitor. KRAS-IN-42 is promising for research of KRAS G12D-mutant cancers (e.g., non-small cell lung cancer, colorectal cancer) .
loading...
    loading...
Cat. No.: HY-180200
CAS No.: 3032602-44-8
Target:  

Ras ERK

Research Areas:  

Cancer

RNK08954 is an orally active KRASG12D inhibitor with a Kd of 0.0395 nM. RNK08954 selectively binds the inactive GDP-bound KRASG12D form, suppresses downstream KRAS-mediated signaling pathways p-ERK1/2 experssion. RNK08954 inhibits KRASG12D-mutant cell proliferation, induces G0-G1 cell cycle arrest, and inhibits tumor growth in mouse xenograft models. RNK08954 can be used for the research of non-small cell lung cancer, pancreatic ductal adenocarcinoma .
loading...
    loading...
Cat. No.: HY-186001
CAS No.: 2922732-38-3
Synonyms: RM-044
Target:  

Ras β-catenin

Research Areas:  

Cancer

RMC-9945 (RM-044) is a selective, covalent, and orally active RAS (ON) G12D inhibitor. RMC-9945 enhances the transcriptional activity of β-Catenin/TCF. RMC-9945 induces cell state transition, forcing metastatic colorectal cancer cells to switch from the Emp1 + state to the Lgr5 + stem cell-like state. RMC-9945 achieves durable disease control in preclinical models of colorectal cancer with early liver metastasis, but shows reduced activity in late-stage metastasis models. RMC-9945 can be used in research related to metastatic colorectal cancer and pancreatic ductal adenocarcinoma .
loading...
    loading...